Y-mAbs Therapeutics's revenue for the
three
months ended in Dec. 2023 was $23.36 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $84.82 Mil.
Y-mAbs Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $0.54.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.94.
During the past 12 months, the average Revenue per Share Growth Rate of Y-mAbs Therapeutics was 30.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 55.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Y-mAbs Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 55.50% per year. The lowest was 55.50% per year. And the median was 55.50% per year.
Y-mAbs Therapeutics Revenue Historical Data
The historical data trend for Y-mAbs Therapeutics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Y-mAbs Therapeutics's Revenue
For the Biotechnology subindustry, Y-mAbs Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y-mAbs Therapeutics's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's Revenue falls into.
Y-mAbs Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $84.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Y-mAbs Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMAB has been successfully added to your 